Pretransplantation demographic and clinical characteristics of study cohort, stratified by CR status
| . | All (n = 253) . | CR1 (n = 183) . | CR2 (n =70) . | P* . |
|---|---|---|---|---|
| Median age at HCT (range), y | 43.1 (0.6-72.6) | 44.7 (0.6-69.5) | 42.3 (2.1-72.6) | NS |
| Male gender, n (%) | 131 (51.8%) | 92 (50.3%) | 39 (55.7%) | NS |
| Median WBC at diagnosis, ×103/µL | 9.6 (0.2-326) | 8.6 (0.2-280) | 14.9 (1.2-326) | NS |
| Cytogenetics, n (%) | <.001 | |||
| Favorable | 22 (8.7%) | 6 (3.3%) | 16 (22.9%) | |
| Intermediate | 168 (66.4%) | 124 (67.8%) | 44 (62.9%) | |
| Adverse | 56 (22.1%) | 48 (26.2%) | 8 (11.4%) | |
| Missing | 7 (2.8%) | 5 (2.7%) | 2 (2.9%) | |
| Secondary AML, n (%) | 69 (27.3%) | 63 (34.4%) | 6 (8.6%) | <.001 |
| No. of induction courses, n (%) | .014 | |||
| 1 | 167 (66.0%) | 109 (59.6%) | 58 (82.9%) | |
| 2 | 75 (29.6%) | 64 (35.0%) | 11 (15.7%) | |
| ≥3 | 11 (4.3%) | 10 (5.5%) | 1 (1.4%) | |
| Consolidation after initial induction, n (%) | .006 | |||
| No | 40 (15.8%) | 36 (19.7%) | 4 (5.7%) | |
| Yes | 213 (84.2%) | 147 (80.3%) | 66 (94.3%) | |
| No. of consolidation courses | <.001 | |||
| 1 | 111 (43.9%) | 93 (50.8%) | 18 (25.7%) | |
| ≥2 | 102 (40.3%) | 54 (29.5%) | 48 (68.6%) | |
| No. of re-induction courses, n (%) | NA | |||
| 1 | — | NA | 57 (81.4%) | |
| 2 | — | NA | 10 (14.3%) | |
| ≥3 | — | NA | 3 (4.3%) | |
| Consolidation after re-induction, n (%) | NA | |||
| No | — | NA | 46 (65.7%) | |
| Yes | — | NA | 24 (34.3%) | |
| No. of consolidation courses | ||||
| 1 | — | NA | 22 (31.4%) | |
| ≥2 | — | NA | 2 (2.9%) | |
| Median remission duration before HCT (range), days | 121 (16-465) | 59.5 (17-231) | <.001 | |
| Peripheral blood counts before HCT | .001 | |||
| ANC ≥1 000/µL and platelets ≥100 000/µL | 216 (85.4%) | 164 (89.6%) | 52 (74.3%) | |
| ANC <1 000/µL and/or platelets <100 000/µL | 36 (14.2%) | 18 (9.8%) | 18 (25.7%) | |
| Missing | 1 (0.4%) | 1 (0.6%) | 0 (0%) | |
| Routine cytogenetics before HCT | NS | |||
| Normal karyotype | 222 (87.8%) | 159 (86.9%) | 63 (90.0%) | |
| Abnormal karyotype | 24 (9.5%) | 20 (10.9%) | 4 (5.7%) | |
| Missing/inadequate data | 7 (2.8%) | 4 (2.2%) | 3 (4.3%) | |
| MRD status at HCT | NS | |||
| Positive, n (%) | 54 (21.3%) | 36 (19.7%) | 18 (25.7%) | |
| <0.1% | 14 (5.5%) | 12 (6.6%) | 2 (2.9%) | |
| 0.1%-1% | 24 (9.5%) | 14 (7.7%) | 10 (14.3%) | |
| >1% | 16 (6.3%) | 10 (5.5%) | 6 (8.6%) | |
| Median % abnormal blasts, range | 0.30 (0.007-7.8) | 0.29 (0.007-7.8) | 0.41 (0.05-3.5) | |
| Negative, n (%) | 199 (78.7%) | 147 (80.3%) | 52 (74.3%) |
| . | All (n = 253) . | CR1 (n = 183) . | CR2 (n =70) . | P* . |
|---|---|---|---|---|
| Median age at HCT (range), y | 43.1 (0.6-72.6) | 44.7 (0.6-69.5) | 42.3 (2.1-72.6) | NS |
| Male gender, n (%) | 131 (51.8%) | 92 (50.3%) | 39 (55.7%) | NS |
| Median WBC at diagnosis, ×103/µL | 9.6 (0.2-326) | 8.6 (0.2-280) | 14.9 (1.2-326) | NS |
| Cytogenetics, n (%) | <.001 | |||
| Favorable | 22 (8.7%) | 6 (3.3%) | 16 (22.9%) | |
| Intermediate | 168 (66.4%) | 124 (67.8%) | 44 (62.9%) | |
| Adverse | 56 (22.1%) | 48 (26.2%) | 8 (11.4%) | |
| Missing | 7 (2.8%) | 5 (2.7%) | 2 (2.9%) | |
| Secondary AML, n (%) | 69 (27.3%) | 63 (34.4%) | 6 (8.6%) | <.001 |
| No. of induction courses, n (%) | .014 | |||
| 1 | 167 (66.0%) | 109 (59.6%) | 58 (82.9%) | |
| 2 | 75 (29.6%) | 64 (35.0%) | 11 (15.7%) | |
| ≥3 | 11 (4.3%) | 10 (5.5%) | 1 (1.4%) | |
| Consolidation after initial induction, n (%) | .006 | |||
| No | 40 (15.8%) | 36 (19.7%) | 4 (5.7%) | |
| Yes | 213 (84.2%) | 147 (80.3%) | 66 (94.3%) | |
| No. of consolidation courses | <.001 | |||
| 1 | 111 (43.9%) | 93 (50.8%) | 18 (25.7%) | |
| ≥2 | 102 (40.3%) | 54 (29.5%) | 48 (68.6%) | |
| No. of re-induction courses, n (%) | NA | |||
| 1 | — | NA | 57 (81.4%) | |
| 2 | — | NA | 10 (14.3%) | |
| ≥3 | — | NA | 3 (4.3%) | |
| Consolidation after re-induction, n (%) | NA | |||
| No | — | NA | 46 (65.7%) | |
| Yes | — | NA | 24 (34.3%) | |
| No. of consolidation courses | ||||
| 1 | — | NA | 22 (31.4%) | |
| ≥2 | — | NA | 2 (2.9%) | |
| Median remission duration before HCT (range), days | 121 (16-465) | 59.5 (17-231) | <.001 | |
| Peripheral blood counts before HCT | .001 | |||
| ANC ≥1 000/µL and platelets ≥100 000/µL | 216 (85.4%) | 164 (89.6%) | 52 (74.3%) | |
| ANC <1 000/µL and/or platelets <100 000/µL | 36 (14.2%) | 18 (9.8%) | 18 (25.7%) | |
| Missing | 1 (0.4%) | 1 (0.6%) | 0 (0%) | |
| Routine cytogenetics before HCT | NS | |||
| Normal karyotype | 222 (87.8%) | 159 (86.9%) | 63 (90.0%) | |
| Abnormal karyotype | 24 (9.5%) | 20 (10.9%) | 4 (5.7%) | |
| Missing/inadequate data | 7 (2.8%) | 4 (2.2%) | 3 (4.3%) | |
| MRD status at HCT | NS | |||
| Positive, n (%) | 54 (21.3%) | 36 (19.7%) | 18 (25.7%) | |
| <0.1% | 14 (5.5%) | 12 (6.6%) | 2 (2.9%) | |
| 0.1%-1% | 24 (9.5%) | 14 (7.7%) | 10 (14.3%) | |
| >1% | 16 (6.3%) | 10 (5.5%) | 6 (8.6%) | |
| Median % abnormal blasts, range | 0.30 (0.007-7.8) | 0.29 (0.007-7.8) | 0.41 (0.05-3.5) | |
| Negative, n (%) | 199 (78.7%) | 147 (80.3%) | 52 (74.3%) |
ANC, absolute neutrophil count; NA, not applicable; NS, not significant; WBC, white blood cell count.
For the comparison CR1 vs CR2.